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Abstract
Mucosal immunity is central to sexual transmission and overall pathogenesis of HIV-1 infection, but the ability of vaccines to
induce immune responses in mucosal tissue compartments is poorly defined. Because macaque vaccine studies suggest
that inguinal (versus limb) vaccination may better target sexually-exposed mucosa, we performed a randomized, double-
blinded, placebo-controlled Phase I trial in HIV-1-uninfected volunteers, using the recombinant Canarypox (CP) vaccine
vCP205 delivered by different routes. 12 persons received vaccine and 6 received placebo, divided evenly between deltoid-
intramuscular (deltoid-IM) or inguinal-subcutaneous (inguinal-SC) injection routes. The most significant safety events were
injection site reactions (Grade 3) in one inguinal vaccinee. CP-specific antibodies were detected in the blood of all 12
vaccinees by Day 24, while HIV-1-specific antibodies were observed in the blood and gut mucosa of 1/9 and 4/9 evaluated
vaccinees respectively, with gut antibodies appearing earlier in inguinal vaccinees (24–180 versus 180–365 days). HIV-1-
specific CD8+ T lymphocytes (CTLs) were observed in 7/12 vaccinees, and blood and gut targeting were distinct. Within
blood, both deltoid and inguinal responders had detectable CTL responses by 17–24 days; inguinal responders had early
responses (within 10 days) while deltoid responders had later responses (24–180 days) in gut mucosa. Our results
demonstrate relative safety of inguinal vaccination and qualitative or quantitative compartmentalization of immune
responses between blood and gut mucosa, and highlight the importance of not only evaluating early blood responses to
HIV-1 vaccines but also mucosal responses over time.
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Introduction
As of 2010, 34 million people were living with HIV-1 infection
and 2.7 million new infections occurred that year alone (UNAIDS
World AIDS Day report 2011). Although antiretroviral therapy
(ART) is effective, it is costly, and requires lifelong administration
and continuous monitoring, which is limiting in resource-poor
endemic regions. Thus, the development of a safe and effective
vaccine against HIV-1 remains a critical goal to stem the
pandemic. Of over 30 vaccine candidates tested in human trials,
only one has shown a hint of efficacy [1] in preventing HIV-1
acquisition, and none have had any effect on immune control after
infection [2].
The vast majority of HIV-1 transmissions occur through sexual
contact and exposure of mucosal surfaces. Mucosal tissues of the
genital and intestinal tracts are pro-inflammatory environments
rich in activated CD4+ T-cells, which are the preferred targets for
HIV-1 infection. Numerous studies in non-human primates and
humans have demonstrated that the gut mucosa, which contains
about the 50% of total body lymphocytes [3], is the predominant
site of early HIV-1 replication and amplification regardless the
route of infection[4]. Moreover, the mucosal immune system is
compartmentalized; immune responses to the same antigen(s) can
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differ between anatomic compartments in terms of specificity,
avidity and memory T cell phenotypes [5–7]. Thus it is clear that
the mucosa is a key site for eliciting protective immunity by novel
vaccine strategies against HIV-1.
Systemic immunization has been proven to be adequate for
most vaccines, including some against mucosal pathogens. There
is evidence, however, that mucosal immunity can play an
important role in protection but is dependent on the route of
vaccine administration. Oral polio vaccine (live attenuated)
generates gut mucosal immunity that limits subsequent shedding
of poliovirus after infection, while shedding in stool is noted after
vaccination via deltoid intramuscular injection (inactivated),
although both vaccines prevent systemic dissemination and
poliomyelitis [8]. Murine and macaque vaccination models
indicate compartmentalization of the immune system and the
potential importance of the route of vaccine delivery [5,9,10].
Here, we utilize the HIV-1-recombinant Canarypox vaccine
ALVAC-HIV vCP205 to examine blood versus gut mucosal
immune responses when the vaccine is delivered via two different
vaccination routes: deltoid/intramuscular (deltoid-IM) versus
inguinal/subcutaneous (inguinal-SC).
Materials and Methods
The protocol for this trial and supporting CONSORT checklist
are available as supporting information; see Checklist S1 and
Protocol S1.
Ethics Statement
This study was approved by the UCLA Office of the Human
Research Protection Program Institutional Review Board (UCLA
IRB #10-000520) with all participants providing written informed
consent.
Objectives
The objectives of this Phase 1 trial were to (i) evaluate the safety
of inguinal immunization using an already human-evaluated HIV-
1 vaccine [11,12], (ii) define and compare differences in immune
responses to the vaccine carrier (canarypox) and HIV-1 proteins in
blood and gastrointestinal mucosal biopsy samples. The working
hypotheses were that the inguinal immunization route would be
safe, that both mucosal antibody and CD8+ T lmphocyte
responses would be detectable in gut mucosa and blood, and that
blood and gut mucosa responses would differ. The protocol was
designed by the investigators with collaborative input and IND-
support from Aventis Pasteur (now Sanofi Pasteur). This Phase 1
interventional clinical trial started recruitment in October 2003,
enrolling the first subject 11/17/03 and ending follow-up of the
last patient 7/27/05. This predated the requirements for pre-
registration with ClinicalTrials.gov (7/1/05) and CONSORT
(www.consort-statement.org) compliance. However, this study was
registered with ClinicalTrials.gov on 3/4/04 (NCT00076817).
Study subjects
Study inclusion criteria included willingness to avoid any rectal
insertions one week prior to vaccination and one week before/
after each flexible sigmoidoscopy. Exclusion criteria included
HIV-1 infection, any chronic gastrointestinal disorder, history of
significant gastrointestinal bleeding, or other significant medical
disorders. Enrollment was protocol-defined as having met initial
screening criteria, providing written informed consent, and having
negative evaluations for HIV-1 or sexually transmitted infections
(syphilis, Chlamydia trachomatis and Neisseria gonorrhea and active
Herpes simplex lesions). Female participants were required to be
using an acceptable form of contraception. Prospective vaccinees
were briefed on the risks and benefits of the ALVAC vCP205
candidate vaccine (Sanofi Pasteur) and the potential implications
vaccine-induced positive HIV-1 serology [13]. 22 men and women
aged 25–60 years were enrolled; 18 persons met randomization
criteria and proceeded to receive vaccinations.
Vaccine
The live recombinant canarypox vaccine ALVAC vCP205
containing HIV-1 IIIB env/gag/protease was produced under GMP
conditions and provided by Sanofi Pasteur. The IND application
to the FDA for a new site of administration (inguinal-subcutane-
ous) was supported by Sanofi Pasteur and held by Dr. Anton/
UCLA. AP also provided placebo vaccine, a mixture of virus
stabilizer and freeze-drying medium with a diluent for reconsti-
tution. The diluent was 1 mL of sterile pyrogen-free 0.4% sodium
chloride.
Study design
This was a single site, double-blinded, placebo-controlled,
randomized (2:1; vaccine: placebo), Phase 1 trial of the vCP205
vaccine administered via deltoid intramuscular (deltoid-IM) versus
inguinal subcutaneous (inguinal-SC) vaccinations. Participants
were defined as ‘‘enrolled’’ after completing baseline examinations
but prior to receiving the first vaccination. Randomization, which
was not stratified by any baseline covariate, was performed by a
study statistician working directly with the research pharmacy.
Participants were randomized first to receive either placebo (n= 6)
or vCP205 vaccine (n = 12). The subjects within each of those
groups then were randomized into equal numbers to receive
injections either via deltoid-intramuscular or inguinal-subcutane-
ous routes (placebo deltoid n= 3, placebo inguinal n= 3, vaccine
deltoid n= 6, vaccine inguinal n= 6). All vaccinations were
administered in a double-blinded fashion (the syringes and their
contents were visually indistinguishable between placebo and
vaccine), and all study staff remained blinded to randomization
codes until data lockdown by the study statistician following the
pre-determined data quality management protocol. Plasma HIV-1
RNA was measured at each study visit to detect any interval/
intercurrent infections. Participants were given a symptom diary
and encouraged to call/report any unexpected symptoms, and
were called daily by the study coordinator for the week following
each vaccination. The primary objective was to determine the
safety profile of the vaccine. Secondary objectives were to
determine: (i) whether deltoid and inguinal vaccinations induced
differential immune responses (humoral and cellular); (ii) if
detectable mucosal responses arose; and (iii) whether mucosal
responses varied by vaccination route and matched those seen in
blood. The overall study design is summarized in Figure 1.
Vaccination schedule
Following two baseline mucosal and blood sample acquisitions
(at Day -28 and Day -14, prior to first immunization), vaccinations
were administered at week 0 (106 TCID50) and then weekly for 3
weeks (107 TCID50). Inguinal-SC immunizations were adminis-
tered by injection medial to the femoral vein, a modification of a
previously described, targeted iliac lymph node (TILN) protocol
[14]. Deltoid-IM immunizations were delivered per routine
clinical protocols. Both deltoid-IM and inguinal-SC vaccinations
were alternatively administered to the left and right limbs.
Inguinal Versus Deltoid HIV Vaccination
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Mucosal sampling
Mucosal sampling was performed as previously described [15–
17] during the two baseline visits and then three days (62 day
window) after the subsequent 3 vaccinations, and finally at Day
180 and Day 365 after the first vaccination. During each sampling,
anoscopy was first performed for placement of two, pre-moistened
surgical sponges (Ultracell H Medical Technologies, North
Stonington, CT) for 5 minutes to collect mucosal secretions for
antibody quantification [18]. Flexible sigmoidoscopy was then
performed with 20 biopsies acquired at approximately 30 cm from
the anal verge as previously described [15,17,19], for isolation of
mucosal mononuclear cells (MMC). Briefly, biopsies
(8 mm62 mm61 mm from large-cup, endoscopic biopsy forceps
(Microvasive Radial Jaw #1589, outside diameter 3.3 mm) were
taken and immediately placed into 15 ml of tissue culture medium
(RPMI 1640, Irvine Scientific).
Elution of rectal secretions from surgical sponges
Elution of rectal secretions from the surgical sponges was
performed with minor modifications of a previously described
protocol [18]. Briefly, collected sponges were immediately
transported to the laboratory on ice and frozen at 280uC for
later batch processing. Sponge contents were eluted twice with
250 ml cold PBS containing 0.25% BSA (Sigma Chemicals, St
Louis, MO), 1% Igepal (Sigma Chemicals, St. Louis, MO) and 16
protease inhibitor cocktail (Sigma Chemicals, St. Louis, MO) by
centrifugation (10,000 rpm in a 5415D EppendorfTM centrifuge
for 30 minutes at 4uC). The recovered volume from the sponge
was calculated by subtracting the volume recovered from negative
control sponges from the total recovered volume. Duplicate
samples were pooled, frozen, and retrieved in batches for further
analysis.
Evaluation of HIV-1-specific and canarypox-specific
antibody responses
Total HIV-1-specific immunoglobulin was quantified in plasma
and rectal secretions at baseline as well as longitudinally post-
immunization (Days 10, 17, 24, 180, and 365). Quantification of
HIV-1-specific antibodies was performed with a modification of a
previously described protocol [20] using the VironostikaH HIV-1
MICROELISA system (Organon Teknika Corp, Durham, NC).
Samples were run according to the manufacturer’s instructions
with the addition of a standard curve generated using serial
dilutions (10–3000 ng/ml) of human anti-HIV-1 gp120/160 IgG
(Immuno Diagnostics, Inc.Woburn,MA). Total IgG and total IgA
were quantified in the eluted rectal secretions or plasma by ELISA
as previously reported [18,19]. In brief, 96-well plates (Corning
Inc., Corning, NY) were coated overnight at 4uC with rabbit anti-
human IgG or IgA (Dako Corp, Carpenteria, CA) diluted 1/6000
in bicarbonate buffer (pH 9.6). Serially diluted standard curves
utilized purified human immunoglobulin (IgG or IgA) ranging
from 7.8–500 ng/ml (Jackson Immunoresearch Laboratories,
West Grove, PA). Samples were run in duplicate, along with a
positive control sample, for which performance characteristics and
acceptable ranges had been previously established [21,22]. Plates
were incubated for 60 min at 37uC, and washed five times in wash
buffer prior to the addition of 100 ml of peroxidase conjugated
rabbit anti-human IgG or IgA (Dako Corp, Carpenteria, CA).
Absorbance was read at 492 nm using a Benchmark Plus ELISA
plate reader (Biorad, Hercules, CA) equipped with Microplate
MangerH software. Values were expressed in ng/ml as extrapo-
lated from standard curves, and the means were calculated for
each sample. Final ELISA results were expressed in units of anti-
HIV-1/mg of total IgG+IgA. Canarypox-specific antibodies in
blood (IgG only) and rectal secretions (IgG+IgA) were detected by
ELISA (supplies and protocol courtesy of Sanofi Pasteur) at the
same time points.
Isolation of mucosal mononuclear cells
Colonic mucosal mononuclear cells (MMC) were isolated from
the sigmoid colon biopsies as previously reported [15,17]. Briefly,
biopsy samples were washed, collagenase digested, and disrupted
into single cell suspensions in medium containing piperacillin-
tazobactam antibiotic (Zosyn, Wyeth Co., Philadelphia, PA) and
amphotericin B (Fungizone, GIBCO Invitrogen, Carlsbad, CA).
This procedure routinely yielded between 2 to 56106 viable CD3+
T lymphocytes per 17 biopsies. Cell yield and phenotypes were
quantified with Multi-Test staining and TRUCount beads (Becton
Dickinson Immunocytometry Systems, San Jose, CA) respectively.
The remaining biopsies were used for histology and tissue banking
for later studies (IRB-approved).
Polyclonal expansion of CD8+ T lymphocytes from PBMCs
and MMCs
To obtain adequate numbers of CD8+ T lymphocytes (CTLs)
for measurements of vaccine responses, CTLs from MMC and
PBMC preparations were polyclonal expanded using a CD3:CD4
bi-specific monoclonal antibody as previously described [19].
Briefly, the cells were cultured for 14 days with the antibody
(which inhibits CD4+ T lymphocyte growth and stimulates CD8+
T lymphocyte growth) plus IL-2 (with additional irradiated
autologous feeder PBMC for MMC expansions). This procedure
produces polyclonal expanded CTLs with minimal bias compared
to non-expanded lymphocytes [19,22–24]. Average yield of
expanded CD3+ T lymphocytes was about 26107 expanded cells
from 106 fresh MMC [22]. Verification of expanded CTL
numbers was performed using 3-color flow cytometry (CD3/
CD4/CD8) and routinely demonstrated .85% purity of expand-
ed CTLs from MMC and .95% from PBMC with a viability
above 90% (data not shown).
Evaluation of HIV-1-specific CD8+ T lymphocyte
responses
Standard IFN-c ELISpot assays were performed using bulk
expanded CTLs as previously reported [21,22,24]. In brief, these
cells were derived from MMC and PBMC [19] and then screened
using a library of 15-mer peptides consecutively overlapping by 11
amino acids spanning the entire HIV-1 proteome sequence (NIH
AIDS Research and Reference Reagent Repository catalogue
numbers 8116, 6208, 9487, 5189, 5138, 6445, 6447, 6444, 6446),
followed by reading with an automated ELISpot counting system
(Cellular Technologies Limited, Cleveland, OH). Screening was
performed against 53 pools of 12–16 consecutive peptides. Results
for reactivity against peptide pools spanning protein sequences
contained in the vaccine were expressed as spot-forming cells
(SFC) per 106 CTLs after background-subtracting the mean of the
Figure 1. Clinical trial design. A. CONSORT flowchart of subject enrolment. B. After an initial screening visit, blood and gut mucosal biopsies were
obtained 28 and 14 days before initiation of vaccination. Vaccinations (vCP205 or placebo) were administered Days 0, 7, 14, 21. Blood samples then
were collected on Days 10, 17, 24, 180, and 360. Gut mucosal biopsies were collected at Days 10, 24, 180, 360.
doi:10.1371/journal.pone.0088621.g001
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negative controls (consisting of peptide pools spanning protein
sequences not contained in the vaccine, generally ,50 SFC/well,
usually ,20 SFC/well). Baseline responses before treatment were
established for every subject. These responses gave a false positive
rate of 1.5%. The mean of the baseline responses was 25.5 SFC/
106 CTLs (95% CI 27.4 to 23.6).
Statistical Analysis
Statistical analyses were carried out with MinitabH Statistical
Software (State College, PA). The Wilcoxon Signed-Rank Test
was used for comparisons of measurements from the same person
across different time points. The Mann-Whitney test was utilized
to compare groups of values, i.e. measurements from persons who
received placebo versus vaccine, and measurements in the blood
versus gut compartments. Note that in the blood versus gut
compartment comparisons, both paired and non-paired non-
parametric analyses were performed (to cover both possible
assumptions regarding dependency between compartments) and
yielded almost identical results. Statistical significance was defined
as a p value for the null hypothesis of ,0.05.
Results
Participant demographics
Twenty-two subjects enrolled in the study, of which three were
found ineligible (out of range laboratory tests, initial non-disclosure
of intravenous drug use, initial non-disclosure of HIV seropositiv-
ity) and one was withdrawn due to non-compliance; none of these
received vaccinations. Eighteen study subjects including nine
males and nine females (Table 1) were randomized to receive
vaccine/placebo injections via either deltoid-IM or inguinal-SC
injections. The median age was 39 years (range 25–60).
Among vCP205 vaccinees, six of six tolerated deltoid
intramuscular vaccinations, and four of six tolerated
inguinal subcutaneous vaccinations
All 18 subjects completed all protocol visits, although 2/18 in
the inguinal vaccine group (Subjects C and M) had adverse events
(AEs) at the injection sites after the 2nd vaccination and did not
receive subsequent vaccinations. Among placebo vaccinees, all
AEs in both deltoid and inguinal groups were mild (grade 1 or 2).
Among the six deltoid-IM vaccinees, there were 31 grade 1, 3
grade 2, and no grade 3 or 4 AEs. Among the six inguinal-SC
vaccinees, there were 29 grade 1, 5 grade 2, 3 grade 3, and no
grade 4 AEs. All grade 3 AEs were in the same individual receiving
vaccine (Subject M), who had swelling, tenderness, and erythema
at the injection site. Of the six inguinal-SC vaccinees, Subjects C
and M halted vaccinations due to injection site inflammation after
the second vaccination; the symptoms resolved spontaneously and
these two subjects completed the full monitoring and sample
collection protocol. Thus, in contrast to deltoid-IM vaccination
with vCP205, inguinal-SC vaccination was not entirely safe.
One subject (Subject S) in the deltoid-IM placebo group had
true HIV-1 infection detected only at the final study visit (Day 365)
demonstrating 9,870 copies/ml of plasma HIV-1 RNA, and
reactive serum anti-HIV antibodies confirmed by Western blot
including reactivity against non-vaccine HIV-1 proteins. All HIV
testing at the prior study visit (Day 180) had been negative.
All vaccinees had humoral responses against the
canarypox vector in blood but not in rectal mucosa
The 12 vaccinees were assessed for their canarypox-specific
antibody responses in blood plasma (IgG) and gut secretions (IgG
and IgA) three days after the fourth weekly immunization (Day
24). Blood (Figure 2a) demonstrated significant anti-canarypox
responses for both deltoid (p=0.019) and inguinal (p=0.001)
groups. In contrast, there were no statistically significant IgG or
IgA responses against canarypox in the gut (Figure 2b), although
there was an increase for IgA in deltoid vaccinees that did not
reach statistical significance. Overall, there were no significant
differences in canarypox humoral responses for deltoid versus
inguinal vaccination.
HIV-1-specific antibodies developed slowly in the gut
and remained essentially undetectable in the blood
HIV-1-specific blood and gut mucosal antibody responses were
longitudinally assessed over the 365 days after first immunization
(Table 2). In blood, only one vaccinee (Subject B) had detectable
HIV-1-specific antibodies. Gut mucosal responses were observed
on Day 180 when 2/9 (22%) vaccinees had detectable HIV-1-
specific antibodies (0/4 deltoid and 2/5 inguinal vaccinees). This
increased on Day 365 to 3/9 (33%) of evaluated vaccinees (2/4
deltoid and 1/5 inguinal vaccinees). Only 1 participant (Subject F)
demonstrated repeated antibody responses on Days 180 and 365,
and only in the gut. Placebo recipients had no HIV-1-specific
antibodies at any time point, except for one person who actually
sustained HIV-1 infection between Days 180 and 365 (Subject S).
As a whole, these data demonstrate that detectable humoral
responses against the HIV-1 portion of the vaccine appeared only
in the gut, not blood, and were observed late (after 24 days, up to
180 days or later).
Inguinal immunization induced HIV-1-specific CTL
responses in both blood and gut
The two vaccination groups were compared for CTL responses
in both blood and gut mucosa. On Days 0, 10, 17, 24, 180, and
Table 1. Participant demographics.
Subject Age Sex Ethnicity
Placebo Inguinal H 42 F African-American
J 47 F Caucasian
U 60 F Caucasian
Deltoid D 25 F Caucasian
K 45 F African-American
S 37 M Caucasian
Vaccine Inguinal C 54 M Caucasian
F 55 F African-American
G 47 M Caucasian
M 26 M Caucasian
O 38 M African-American
Q 30 M Caucasian
Deltoid B 38 F Caucasian
I 35 M Caucasian
N 25 M Caucasian
R 42 M Asian-American
T 29 F Asian-American
V 40 F Caucasian
doi:10.1371/journal.pone.0088621.t001
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365 after the first vaccination, HIV-1-specific CTL responses were
assessed in both compartments by IFN-c ELISpot assay for
reactivity against the HIV-1 protein sequences expressed by
vCP205. Baseline responses before treatment were established for
each subject in both compartments. The mean of the baseline
background-subtracted responses was 25.51 (95% CI 27.42 to
23.62) spot-forming cells per million CD8+ T lymphocytes, with a
false positive rate of 1.5%. In blood (Figure 3a), there was a
significant increase in HIV-1-reactivity (p=0.004) by Day 24. For
gut (Figure 3b), the response was borderline significant on Day 180
(p=0.052) and significant on Day 365 (p,0.001).
Across groups, there appeared to be compartment-specific
differences in HIV-1-specific CTL responses based on vaccination
route. In blood (Figure 4 top panels) the timing was similar for
both vaccination routes, achieving significance by Day 17
(p=0.001 and p=0.036 for deltoid-IM and inguinal-SC vaccinees,
respectively) and Day 24 (p=0.042 and p=0.012). There was a
suggestion that blood responses were higher in magnitude on Day
24 in the deltoid versus inguinal group (mean 167 versus 91,
p=0.21). In gut mucosa (Figure 4 bottom panels), however, only
the deltoid vaccination group achieved significant responses and
then only on Day 365 (p,0.001), although a non-significant
increase was observed on Day 180. There were several early gut
mucosal responses in inguinal vaccinees, but these did not reach
significance across the group. Overall, these analyses of pooled
group data suggest that deltoid vaccination may induce higher
magnitude CTL responses in blood than inguinal vaccination at
the early time points examined, and that there may be kinetic
differences in the different compartments varying by vaccination
route.
HIV-1-specific CTL responses were generated earlier in
blood than gut
Examining HIV-1-specific CTL responses within individual
vaccinees, defined as interferon-c ELISpot measurements of $50
spot-forming cells per million CD8+ T lymphocytes, responses in
blood and gut mucosa displayed different kinetics.
By this criterion, 4/12 (33%) vaccinees had detectable blood
responses, including two from each vaccination group (Figure 5
top panels). The deltoid vaccination responders appeared to have
higher magnitude and breadth of responses compared to inguinal
vaccinees at the tested time points, consistent with the overall
group comparisons. The two deltoid vaccine responders recog-
nized 4 peptide pools per person, whereas the two inguinal vaccine
responders recognized 1 and 2 pools. Both groups had detectable
CTL responses within 24 days after vaccination initiation.
Within gut mucosa, 6/12 (50%) vaccinees had CTL responses,
including three from each vaccination group (Figure 5 bottom
panels). In contrast to the blood, the kinetics of responses appeared
different between the groups. The deltoid vaccine responders had
highest magnitudes observed at Day 180, while the inguinal
vaccine responders had highest magnitudes on Day 17 (p=0.0357
by Chi square test). Also in contrast to blood, the breadth of CTL
responses was similar between groups, ranging from 1 to 3 peptide
pools for each individual. These data suggest that the route of
vaccination protocol influences the kinetics and magnitude of
HIV-1-specific responses in blood and gut mucosal compartments,
with deltoid vaccination eliciting higher magnitude and broader
responses in the blood and delayed responses in the gut mucosa
compared to inguinal vaccination, for the time points tested.
CTL targeting of HIV-1 was discordant between blood
and gut compartments within individuals and affected
by vaccination route
CTL responses against peptide pools were compared between
blood and gut in each responder (Figure 6). One deltoid vaccinee
(Subject R) displayed responses to 3 pools in the gut only. The
other two deltoid vaccinees (Subjects B and T) each had 3
responses only in the blood, one concordant response in blood and
gut, and no responses in gut alone. Three of the inguinal vaccinees
(Subjects G, Q, and M) had a predominance of responses in the
gut only, and the fourth (Subject F) had responses in the blood
only; none had concordant CTL responses in both compartments.
Note that because these are measurements with peptide pools,
concordance of CTL responses against peptide pools may
overestimate concordance of recognized epitopes. Overall, how-
ever, these results suggest that deltoid vaccination preferentially
induces CTL responses in blood with some concordance in gut
mucosa, while inguinal vaccination tends to induce more responses
only in the gut mucosal compartment at the time points evaluated.
Figure 2. Mucosal and blood antibody responses against
Canarypox. Anti-Canarypox antibodies were measured by ELISA in
blood (IgG only, Panel A) and gut mucosal secretions (IgG and IgA,
Panels B and C) on Day 24. Responses against placebo or vCP205
vaccine are plotted by vaccination route, as abstract units (normalized
against placebo and background-subtracted). Medians and 95%
confidence intervals are indicated for each group.
doi:10.1371/journal.pone.0088621.g002
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Discussion
Despite the role of mucosal surfaces in sexual transmission of
HIV-1 and the central involvement of the gut in the pathogenesis
of acute and chronic infection, data regarding vaccine responses in
the human gut mucosa are lacking. To date, no large scale clinical
HIV-1 vaccine trial has evaluated immunity in this compartment,
and only one vaccine has demonstrated any hint of clinical
efficacy. This vaccine, tested in the RV144 trial, was a prime-boost
combination of recombinant canarypox (vCP1521) and gp120
subunit (AIDSVax) vaccines, each of which failed to produce their
intended cellular and humoral immune responses when tested
individually. In this study, we utilize vCP205 (based on the same
vector as vCP1521), and test it in an FDA Phase I trial for
capability to elicit gut mucosal immune responses when delivered
in an intensive regimen of 4 weekly administrations, and evaluate
whether inguinal vaccination might augment vaccine-specific
immune responses in the gut.
Past macaque data indicate that inguinal vaccination can boost
mucosal immune responses in comparison to standard intramus-
cular immunizations [11], and our trial evaluated the clinical
feasibility and mucosal immunogenicity of this approach. The data
indicated that the protocol is safe and well tolerated by the
volunteers, similar to our earlier small study examining inguinal
versus deltoid vaccination with a recombinant vaccinia virus HIV-
1 vaccine [20]. In general, the inguinal subcutaneous vaccination
Table 2. Vaccine-induced antibody responses against HIV-1.
Day: 0 10 17 24 180 365
Gut Blood Gut Blood Gut Blood Gut Blood Gut Blood Gut Blood
Placebo Inguinal H - - - - ND - - - - - - -
J - - - - ND - - - - - - -
U - - - - ND - - - - - - -
Deltoid D - - - - ND - - - - - - -
K - - - - ND - - - ND ND - -
Vaccine Inguinal C - - - - ND - - - - - - -
F - - - - ND - - - + - + -
G - - - - ND - - - ND ND ND ND
M - - - - ND - - - - - - -
O - - - - ND - - - - - - -
Q - - - - ND - - - + - - ND
Deltoid B - - - - ND - - - - - + +
I - - - - ND - - - - - - -
N - - - - ND - - - ND ND ND ND
R - - - - ND - - - - - - -
T - - - - ND - - - - - + -
V - - - - ND - - - ND ND ND ND
‘‘-’’: below limits of detection
ND: sample not done.
doi:10.1371/journal.pone.0088621.t002
Figure 3. Total observed CTL responses against HIV-1 in blood and gut mucosal compartments. The background-subtracted CTL
responses of all participants against HIV-1 vaccine peptide pools were summed for persons who received placebo (circles) and vCP205 vaccinations
(squares) and plotted for blood (left) and gut mucosa (right). p-values indicate significant differences between groups by Students t-test.
doi:10.1371/journal.pone.0088621.g003
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route was safe and well tolerated, with only minor localized
injection site symptoms.
Evaluation of humoral immunity showed a discrepancy between
responses to the vector versus its HIV-1 inserts, likely related to the
relatively large proteome of the canarypox vector versus the HIV-
1 inserts, without regard to route of vaccination. After vaccination,
antibodies recognizing canarypox could be detected in the blood
at the Day 24 time point (two days after the last vaccination), but
HIV-1-specific antibodies were not detectable at that time, and
seen only at the next time points of 180 or 365 days in 4/9 tested
individuals. Titers of these antibodies in gut mucosal secretions
were far below those seen in HIV-1-infected persons [20], and
appeared to wane in Subject Q. The requirement of several
months to generate these responses was unexpected, but the data
highlight the compartmentalized nature of blood versus gut
mucosal immunity. Our low blood HIV-1 humoral response rate
is not inconsistent with the generally low responses detected in
blood in trials of recombinant canarypox vaccines without
heterologous priming or boosting [25,26], and may be even lower
due to the short term vaccination in our study (Days 0, 7, 14, 21)
versus the usually prolonged regimens in other studies (Months 0,
1, 3, 6, 69, 612).
While vCP205 vaccine was designed to generate HIV-1-specific
CTL responses, it was found to be weakly immunogenic for HIV-
1-specific CTLs in prior clinical studies [12,25,27]. Our data
demonstrated a blood response rate of 4/12 (33%), similar to the
earlier trials of this vaccine, and a gut mucosal response rate of 6/
12 (50%) overall. Although response rates appeared similar for
deltoid versus inguinal vaccination, there appeared to be a
difference in the kinetics of the responses. Inguinal vaccination
resulted in earlier gut mucosal responses than deltoid vaccination,
suggesting that the closer anatomic proximity of injection yielded
more direct access.
Our data also hinted at compartmentalization of CTL responses
between blood and gut mucosa. Of the seven CTL responders
(Subjects B, F, G, M, R, T, and Q), three had responses in both
compartments (B, T, and Q), one had responses in the blood only
(F), and three had responses in the gut mucosal compartment only
(G, M, and R). For persons targeting both compartments, CTL
targeting demonstrated distinct profiles. The highest magnitude
responses against peptide pools in each compartment were not
observed in the other compartment, which indicated that this was
not an artefact of the limit of detection. It is unclear whether these
results reflected bias due to weak immunogenicity of the vaccine,
in which case a strongly immunogenic vaccine might give
concordant results in both compartments, as we have observed
for HIV-1 infection [22] and others have observed with
recombinant adenovirus vaccination of macaques [28,29]. Still,
the data do suggest that the route of immunization affected the
quantity of antigenic access to the two compartments. The timing
of sampling was based on anticipation that peak responses would
occur soon after the final vaccination, but surprisingly our
Figure 4. HIV-1-specific CTL responses in blood and gut mucosal compartments divided according to vaccination route. The results
in Figure 3 are plotted separate depending on vaccination route for recipients of saline (circles) and vCP205 vaccine (squares). The upper and lower
panels show blood and gut mucosal responses respectively, and the left and right panels give results for persons who received deltoid and inguinal
vaccinations respectively. p-values indicate significant differences between groups by Students t-test.
doi:10.1371/journal.pone.0088621.g004
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Figure 5. Kinetics of HIV-1-specific CTL responses within individuals. CTL responses that achieved a magnitude of $50 spot-forming cells
per million CD8+ T lymphocytes at any time are plotted. The upper and lower panels show blood and gut mucosal responses respectively, and the left
and right panels give results for persons who received deltoid and inguinal vaccinations respectively.
doi:10.1371/journal.pone.0088621.g005
Figure 6. Overlap of HIV-1-specific CTL responses between blood and gut mucosal compartments. For each of the indicated participants
with detected HIV-1-specific CTL responses, a pie chart indicates the fraction of peptide pool responses that were detected in blood only, gut mucosa
only, or both compartments. The size of the circle is proportional to the number of peptide pool responses.
doi:10.1371/journal.pone.0088621.g006
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assessments likely missed peak responses between 24 and 180 days,
rendering comparisons of peak magnitude and breadth of CTL
responses unreliable. Still, there were observed differences at the
evaluated time points, indicating at least differences in the kinetics
of immune responses.
A potentially important difference between our vaccination
protocol and prior macaque inguinal vaccination data showing
better access to the mucosa [11] was the limitation of our inguinal
vaccination to subcutaneous tissue, compared to deep inguinal
vaccinations performed in macaques, prompted by safety
concerns. Still, our results suggested that even subcutaneous
inguinal vaccination might better access the lower gut mucosal
immune compartment, although deltoid intramuscular vaccina-
tion also showed mucosal access, perhaps delayed because those
CTLs trafficked from the periphery. Anatomically, superficial
inguinal lymph nodes drain through muscle and skin, whereas
deep inguinal lymph nodes share drainage with intra-abdominal
structures. Animal data suggest that direct mucosal vaccination is
superior for generating mucosal immune responses [5,10], but it is
unclear whether a replication defective vector would achieve
enough immunogenicity without mucosal injection, which would
be clinically difficult in humans.
In conclusion, this HIV-1 vaccine demonstrated differential
immunogenicity for blood and gut mucosal compartments. The
kinetics and targeting of humoral and CTL responses varied
considerably between these compartments, and there was a
surprising lag in gut mucosal responses after deltoid vaccination.
Our results highlight a potential importance of route of vaccine
administration, and also indicate that short term measurements of
immune responses in the blood are unreliable for assessment of
mucosal immunity from HIV-1 vaccine candidates.
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